CS Cancer Solutions - Structured Oncology Intelligence
Brazil flag

Brazil Cancer Research

Latin America's Research Powerhouse & CAR-T Hub

40%

Death Risk Reduction

Breast cancer breakthrough

1st

CAR-T Hub in Latin America

Regional manufacturing

50%

Lower Treatment Costs

Affordable radiation tech

Major Research Breakthroughs

40% Death Risk Reduction in Breast Cancer

2024

Brazilian researchers achieved a 40% reduction in breast cancer death risk through early detection programs combined with rapid treatment access.

A.C.Camargo Cancer Center

Impact:

Saving thousands of Brazilian women annually

CAR-T Manufacturing Hub for Latin America

2023

Brazil established Latin America's first CAR-T cell therapy manufacturing facility, producing affordable treatments for the entire region.

Hospital Sírio-Libanês

Impact:

Bringing advanced immunotherapy to South America

Pioneering Zika-Cancer Connection Research

2023

Brazilian scientists discovered that Zika virus can selectively kill brain cancer cells, opening new avenues for viral therapy.

University of São Paulo

Impact:

Novel viral approach to treating glioblastoma

Affordable Radiation Therapy Technology

2022-2024

Brazil developed cost-effective linear accelerators for radiation therapy at 50% lower cost, making treatment accessible across South America.

Brazilian medical device companies

Impact:

Expanding radiation access to underserved regions

Tropical Disease-Cancer Interaction Studies

Ongoing

Brazil leads research on how tropical infections affect cancer development and treatment, critical for understanding cancer in tropical regions.

Instituto Nacional de Câncer (INCA)

Impact:

Tailoring cancer care for tropical populations

International Clinical Trial Partnerships

Ongoing

Brazil hosts major international clinical trials, offering Brazilian patients early access to experimental therapies from US and European pharmaceutical companies.

Multiple Brazilian cancer centers

Impact:

Bringing global innovation to South America

Leading Research Institutions

A.C.Camargo Cancer Center

São Paulo

Brazil's premier cancer hospital. Leading research in breast, colorectal, and head/neck cancers. Strong partnerships with US and European institutions.

Key Specialties:

Breast Cancer
Colorectal Cancer
Head & Neck Cancers
Clinical Trials

Instituto Nacional de Câncer (INCA)

Rio de Janeiro

Brazil's national cancer institute. Public health oncology, tropical disease-cancer interactions, and affordable treatment development.

Key Specialties:

Public Health Oncology
Tropical Diseases
Cancer Prevention

Hospital Sírio-Libanês

São Paulo

Latin America's CAR-T therapy hub. Precision medicine and advanced immunotherapy for the region.

Key Specialties:

CAR-T Therapy
Immunotherapy
Precision Medicine
Active Clinical Trials in Brazil

Brazil welcomes international patients to cutting-edge clinical trials

CAR-T for Lymphoma (Latin American Study)

Phase 2

Testing Brazilian-manufactured CAR-T cells for non-Hodgkin lymphoma patients across Latin America.

Hospital Sírio-Libanês
Active recruitment

Zika Virus Therapy for Brain Tumors

Phase 1

Using engineered Zika virus to selectively attack glioblastoma cells while sparing healthy brain tissue.

University of São Paulo
Active recruitment

Breast Cancer Early Detection Program

Population Study

Nationwide breast cancer screening and rapid treatment program aiming to reduce mortality by 50%.

A.C.Camargo Cancer Center, INCA
Ongoing enrollment

Want to learn about more Brazilian clinical trials? Search our database or contact our team.

Clinical Trials in Brazil

Registry-listed trials for Brazil currently tracked in our database, sourced from public trial registries.

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) as Second-line Treatment for Advanced/Metastatic Penile Squamous Cell Carcinoma: PERSEUS TRIAL (LACOG 1924)

Phase II
Not yet recruiting
NCT07815197
View registry record

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) as Second-line Treatment for Advanced/Metastatic Penile Squamous Cell Carcinoma: PERSEUS TRIAL (LACOG 1924)

Phase II
Not yet recruiting
NCT07815197
View registry record

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) as Second-line Treatment for Advanced/Metastatic Vaginal and Vulvar Squamous Cell Carcinoma - ARCANA Trial (LACOG 1724)

Phase II
Not yet recruiting
NCT07804966
View registry record

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) as Second-line Treatment for Advanced/Metastatic Vaginal and Vulvar Squamous Cell Carcinoma - ARCANA Trial (LACOG 1724)

Phase II
Not yet recruiting
NCT07804966
View registry record

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) as Second-line Treatment for Advanced/Metastatic Penile Squamous Cell Carcinoma: PERSEUS TRIAL (LACOG 1924)

Phase II
Not yet recruiting
NCT07815197
View registry record

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) as Second-line Treatment for Advanced/Metastatic Vaginal and Vulvar Squamous Cell Carcinoma - ARCANA Trial (LACOG 1724)

Phase II
Not yet recruiting
NCT07804966
View registry record

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) as Second-line Treatment for Advanced/Metastatic Vaginal and Vulvar Squamous Cell Carcinoma - ARCANA Trial (LACOG 1724)

Phase II
Not yet recruiting
NCT07804966
View registry record

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) as Second-line Treatment for Advanced/Metastatic Penile Squamous Cell Carcinoma: PERSEUS TRIAL (LACOG 1924)

Phase II
Not yet recruiting
NCT07815197
View registry record

A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults

Phase II
Not yet recruiting
NCT05797662
Kaposi Sarcoma
View registry record

A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults

Phase II
Not yet recruiting
NCT05797662
View registry record

A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults

Phase II
Recruiting
NCT05797662
View registry record

A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults

Phase II
Recruiting
NCT05797662
View registry record

Latest Research Ecosystem Developments

Brazil — Brazil is strengthening its position as a global hub for clinical research through increased industry investment, legislative reforms, and major public-private infrastructure projects.

Updated October 14, 2026

National Oncology Complex in Rio de Janeiro

The Brazilian government announced a R$1.1 billion investment to construct an integrated Oncology Campus linked to the National Cancer Institute (INCA) to consolidate services and increase hospital capacity by late 2026.

OncoDaily

Growth in Global Clinical Trial Ranking

Brazil rose to 12th place globally for initiated clinical studies in 2026, up from 18th in 2025, supported by new legislation aimed at increasing process predictability and attractiveness for international sponsors.

ensaiosclinicos.gov.br

Authorization of Advanced CAR-T Cell Therapy Trials

Anvisa authorized Phase 3 clinical trials for the investigational product AZD0120, a CAR-T cell therapy for multiple myeloma, marking a significant step in bringing advanced immunotherapy to Brazilian patients.

ensaiosclinicos.gov.br

Strategic Partnership for Oncology Research Access

Oncoclínicas&Co and Hapvida NotreDame expanded a strategic partnership to integrate oncology patients into clinical research protocols, aiming to increase recruitment diversity and access to advanced therapies across Brazil.

ensaiosclinicos.gov.br

Comprehensive Mapping of Oncology Research Landscape

A 2026 analysis revealed that 78.7% of cancer trials in Brazil are industry-sponsored, with a heavy focus on lung and breast cancers, while highlighting the need for more academic investment in pediatric oncology.

ecancer

This section is refreshed on a recurring schedule. Entries are AI-assisted research signals organized from public oncology sources and should be verified against the original sources. Information is educational and does not constitute medical advice.

Huippu Prodigy Platforms

© 2026 Huippu Prodigy Platforms, LLC.

CS Cancer Solutions is operated by Huippu Prodigy Platforms, LLC.

Public-Source Oncology Research • Educational and Research Use

Structured Oncology Research Intelligence